

**AMENDMENTS TO THE CLAIMS**

The claims as listed below will replace all prior listings and presentations of claims in the above-identified application.

Please add new Claims 74-76 as follows:

1.-47. **(Canceled).**

48. **(Previously Presented)** A method of treating an ocular disorder, comprising:

introducing an implant comprising a therapeutic drug into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber; and

advancing the distal end of said implant into eye tissue adjacent the anterior chamber such that the implant drains aqueous humor from the anterior chamber into a physiologic outflow pathway and the therapeutic drug reaches eye tissue.

49. **(Previously Presented)** The method of Claim 48, wherein the implant is coated with said therapeutic drug.

50. **(Previously Presented)** The method of Claim 48, wherein advancing the implant into eye tissue involves positioning at least a portion of the implant so as to contact a choroid of the eye.

51. **(Previously Presented)** The method of Claim 48, wherein advancing the implant into eye tissue involves positioning a distal end of the implant so as to drain aqueous humor toward a choroid of the eye.

52.-57. **(Canceled).**

58. **(Previously Presented)** A method of treating an ocular disorder, comprising:

introducing an implant comprising a therapeutic drug into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber; and

advancing the distal end of said implant into eye tissue such that the implant is in contact with at least a choroid of the eye.

59. **(Previously Presented)** The method of Claim 58 additionally comprising draining aqueous humor from the anterior chamber into a physiologic outflow pathway through the implant.

60. **(Previously Presented)** The method of Claim 58 additionally comprising controlling aqueous humor flow through a lumen of the implant.

61. **(Previously Presented)** The method of Claim 58, wherein the implant includes a hollow filled with the therapeutic drug.

62. **(Previously Presented)** The method of Claim 58, wherein the implant includes a first portion and a second portion that is appended from the first portion, the first portion including a lumen and the second portion carrying the therapeutic drug.

63. **(Previously Presented)** The method of Claim 58, wherein the therapeutic drug comprises a compound of drugs, at least one of which is therapeutic.

64. **(Previously Presented)** A method of treating an ocular disorder, comprising:

forming an incision in an eye;

inserting an implant through the incision into an anterior chamber of the eye such that at least a distal end of the implant is temporarily in the anterior chamber, the implant comprising a therapeutic drug; and

inserting the distal end of the implant into eye tissue such that the implant drains aqueous humor from the anterior chamber toward a choroid of the eye.

65. **(Previously Presented)** The method of Claim 64 additionally comprising draining aqueous humor from the anterior chamber into a physiologic outflow pathway through the implant.

66. **(Previously Presented)** The method of Claim 64, wherein the implant includes a first portion and a second portion that is appended from the first portion, the first portion including a lumen and the second portion carrying the therapeutic drug.

67. **(Previously Presented)** A method of treating an ocular disorder, comprising:

introducing an implant into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber;

placing the implant in contact with a choroid of the eye by advancing the distal end of the implant into eye tissue, said implant having at least one flow channel;

flowing a fluid, which comprises aqueous humor, along the flow channel of the implant; and

eluting a therapeutic agent from the implant.

68. **(Previously Presented)** The method of Claim 67 additionally comprising advancing the implant through an anterior chamber of the eye toward an implantation site.

69. **(Canceled).**

70. **(Previously Presented)** A method of treating an ocular disorder, comprising:  
providing an implant having at least one lumen extending between an inlet and an outlet, and at least one anchor projecting outwardly from the lumen;  
introducing the implant into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber;  
using the anchor to retain the implant in eye tissue;  
positioning the outlet in tissue so as to fluidically communicate directly with a physiologic outflow pathway; and  
eluting a therapeutic agent from the implant.

71. **(Previously Presented)** The method of Claim 70 additionally comprising advancing the implant through an anterior chamber of the eye toward an implantation site.

72. **(Previously Presented)** The method of Claim 70 wherein the method further comprises advancing the implant through scleral tissue of the eye when positioning the outlet.

73. **(Previously Presented)** A method of treating an ocular disorder, comprising:  
providing an implant having at least one anchor;  
introducing the implant into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber;  
inserting at least a portion of the implant into eye tissue at an implantation site without penetrating through a cornea or a sclera of the eye;  
using the anchor to retain the implant at said implantation site; and  
eluting a therapeutic agent from the implant.

74. **(New)** The method of Claim 73, wherein introducing the implant into the anterior chamber involves forming an incision in corneal tissue.

75. **(New)** The method of Claim 73, wherein introducing the implant into the anterior chamber involves forming an incision proximate a limbus of the eye.

76. **(New)** The method of Claim 73, wherein introducing the implant into the anterior chamber involves forming a self-sealing incision.